RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT

Objective: Acute myeloid leukemia (AML) is the disease of elderly patients. Therefore, a significant number of patients are not suitable for intensive induction chemotherapy. In this study, it was aimed to retrospectively evaluate patients with AML who were treated Venatoclax-based regimens in our c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	EMINE DURAK, MEHMET CAN UGUR, BETUL KOYUNCU, SINEM NAMDAROĞLU, OKTAY BILGIR
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/c246f44a55ce40c3b2e811fe001acfba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c246f44a55ce40c3b2e811fe001acfba
record_format	dspace
spelling	oai:doaj.org-article:c246f44a55ce40c3b2e811fe001acfba2021-11-10T04:34:45ZRETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT2531-137910.1016/j.htct.2021.10.1015https://doaj.org/article/c246f44a55ce40c3b2e811fe001acfba2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011627https://doaj.org/toc/2531-1379Objective: Acute myeloid leukemia (AML) is the disease of elderly patients. Therefore, a significant number of patients are not suitable for intensive induction chemotherapy. In this study, it was aimed to retrospectively evaluate patients with AML who were treated Venatoclax-based regimens in our center. Methodology: The data of the patients who were treated Venatoclax-based regimens with the diagnosis of AML in the Bozyaka Training and Research Hospital Department of Hematology were scanned retrospectively from their files. Results: Data of 11 patients in total were reached. The mean age of the patients was 73.9. 8 of 11 patients were follow-up with diagnosis of AML , 3 patients with MDS RAEB II. Average follow-up time was 13.6 months. 5 patients died during follow-up. HMA +venatoclax was given to 6 patients as first-line, 4 patients second-line and 1 patient third-line therapy. Complete response was found in 3 patients, partial response in 1 patient, stable disease in 1 patient, and refractory disease in 1 patient. Conclusion: Venatoclax is a promising treatment option because it is an oral agent that can be tolerated by elderly patients and improves response rates and survival.EMINE DURAKMEHMET CAN UGURBETUL KOYUNCUSINEM NAMDAROĞLUOKTAY BILGIRElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S35- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 EMINE DURAK MEHMET CAN UGUR BETUL KOYUNCU SINEM NAMDAROĞLU OKTAY BILGIR RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
description	Objective: Acute myeloid leukemia (AML) is the disease of elderly patients. Therefore, a significant number of patients are not suitable for intensive induction chemotherapy. In this study, it was aimed to retrospectively evaluate patients with AML who were treated Venatoclax-based regimens in our center. Methodology: The data of the patients who were treated Venatoclax-based regimens with the diagnosis of AML in the Bozyaka Training and Research Hospital Department of Hematology were scanned retrospectively from their files. Results: Data of 11 patients in total were reached. The mean age of the patients was 73.9. 8 of 11 patients were follow-up with diagnosis of AML , 3 patients with MDS RAEB II. Average follow-up time was 13.6 months. 5 patients died during follow-up. HMA +venatoclax was given to 6 patients as first-line, 4 patients second-line and 1 patient third-line therapy. Complete response was found in 3 patients, partial response in 1 patient, stable disease in 1 patient, and refractory disease in 1 patient. Conclusion: Venatoclax is a promising treatment option because it is an oral agent that can be tolerated by elderly patients and improves response rates and survival.
format	article
author	EMINE DURAK MEHMET CAN UGUR BETUL KOYUNCU SINEM NAMDAROĞLU OKTAY BILGIR
author_facet	EMINE DURAK MEHMET CAN UGUR BETUL KOYUNCU SINEM NAMDAROĞLU OKTAY BILGIR
author_sort	EMINE DURAK
title	RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
title_short	RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
title_full	RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
title_fullStr	RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
title_full_unstemmed	RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
title_sort	retrospective evaluation of patients with acute myeloid leukemia receiving venatoclax-based treatment
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/c246f44a55ce40c3b2e811fe001acfba
work_keys_str_mv	AT eminedurak retrospectiveevaluationofpatientswithacutemyeloidleukemiareceivingvenatoclaxbasedtreatment AT mehmetcanugur retrospectiveevaluationofpatientswithacutemyeloidleukemiareceivingvenatoclaxbasedtreatment AT betulkoyuncu retrospectiveevaluationofpatientswithacutemyeloidleukemiareceivingvenatoclaxbasedtreatment AT sinemnamdaroglu retrospectiveevaluationofpatientswithacutemyeloidleukemiareceivingvenatoclaxbasedtreatment AT oktaybilgir retrospectiveevaluationofpatientswithacutemyeloidleukemiareceivingvenatoclaxbasedtreatment
_version_	1718440594689228800

RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT

Ejemplares similares